BVF PARTNERS L P/IL has bought stock on 67 days since Jan 2016
See Remarks and Footnotes at Kymera Therapeutics, Inc., and 22 other companies
SEC CIK 0001055947 · Filings on SEC.gov ↗
BVF PARTNERS L P/IL's record
3 months after each buy, from the first price a copier could get.
19 buys since 2016 with 3 months of prices.
Companies
- KYMR Kymera Therapeutics, Inc.See Remarks and Footnotes
- MLTX MoonLake ImmunotherapeuticsDirector and 10% owner
- THRD Third Harmonic Bio, Inc.Insider
- PNT Point Biopharma Global Inc.Former 10% Owner
- RPTX Repare Therapeutics Inc.10% owner
- OLMA Olema Pharmaceuticals, Inc.Director and 10% owner
- XOMA XOMA Royalty Corp10% owner
- CTIC Cti Biopharma Corp10% owner
- CGEM Cullinan Therapeutics, Inc.10% owner
- MRUS Merus N.V.10% owner
- IDYA IDEAYA Biosciences, Inc.Insider
- INFI Infinity Pharmaceuticals, Inc.10% owner
- CYTK Cytokinetics, IncorporatedInsider
- FPRX Five Prime Therapeutics, Inc.Insider
- GLYC Glycomimetics Inc10% owner
- CALA Calithera Biosciences, Inc.10% owner
- PIRS Pieris Pharmaceuticals, Inc.10% owner
- CNCE Concert Pharmaceuticals, Inc.10% owner
- IMDZ Immune Design Corp.10% owner
- ARQL Arqule Inc10% owner
- XENE Xenon Pharmaceuticals Inc.10% owner
- CAPS Capstone Holding Corp.Insider
- NVLS 373584310% owner
Every filing
94 filings since Jan 2016, newest first
Xoma Corp
10% owner
Cytokinetics Inc
10% owner
Merus N.V.
10% owner
Merus N.V.
10% owner
Cytokinetics Inc
10% owner
Five Prime Therapeutics, Inc.
10% owner
Five Prime Therapeutics, Inc.
10% owner
Five Prime Therapeutics, Inc.
10% owner
Calithera Biosciences, Inc.
10% owner
Five Prime Therapeutics, Inc.
10% owner
Five Prime Therapeutics, Inc.
10% owner
Pieris Pharmaceuticals, Inc.
10% owner
Glycomimetics Inc
10% owner
Concert Pharmaceuticals, Inc.
10% owner
Xoma Corp
10% owner
Xoma Corp
10% owner
Infinity Pharmaceuticals, Inc.
10% owner
Xoma Corp
10% owner
Xoma Corp
10% owner
Immune Design Corp.
10% owner
Xoma Corp
10% owner
Infinity Pharmaceuticals, Inc.
10% owner
Xoma Corp
10% owner
Xoma Corp
10% owner
Infinity Pharmaceuticals, Inc.
10% owner
Xoma Corp
10% owner
Infinity Pharmaceuticals, Inc.
10% owner
Arqule Inc
10% owner
Arqule Inc
10% owner
Infinity Pharmaceuticals, Inc.
10% owner
Arqule Inc
10% owner
Cti Biopharma Corp
10% owner
Concert Pharmaceuticals, Inc.
10% owner
Concert Pharmaceuticals, Inc.
10% owner
Infinity Pharmaceuticals, Inc.
10% owner
Xenon Pharmaceuticals Inc.
10% owner
Capstone Therapeutics Corp.
Insider
Xenon Pharmaceuticals Inc.
10% owner
Nivalis Therapeutics, Inc.
10% owner
Nivalis Therapeutics, Inc.
10% owner
Nivalis Therapeutics, Inc.
10% owner
Nivalis Therapeutics, Inc.
10% owner
Infinity Pharmaceuticals, Inc.
10% owner
Cti Biopharma Corp
10% owner
About BVF PARTNERS L P/IL
BVF Partners L.P./IL is a biotechnology-focused investment firm and corporate insider that holds significant positions in multiple life sciences companies, including Kymera Therapeutics, Inc. (NASDAQ: KYMR).( At Kymera, BVF Partners and its affiliated funds are reported as a major shareholder and director by deputization, reflecting board representation through a BVF member and coordinated ownership across entities such as Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P., and BVF Partners OS Ltd.( BVF Partners L.P. is listed on Kymera’s insider roster as an affiliated person/insider and 10% beneficial owner through these funds.(
BVF Partners operates as a specialist biotechnology investment partnership, often filing as a group with related general partner entities (BVF I GP LLC, BVF II GP LLC, BVF GP Holdings LLC, BVF Inc) and principal Mark N. Lampert, who is widely associated with the Biotechnology Value Fund platform.( The firm actively manages sizable positions across public biotech companies and is tracked in regulatory filings for substantial insider trading activity, including large purchases and sales in Kymera Therapeutics and other issuers.( Its leadership and operations center on value-driven investing in biotechnology, using pooled limited partnership structures and affiliated vehicles to build concentrated positions and exercise governance influence through board representation and coordinated insider filings.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.